Tag:

rolapitant

Latest Headlines

Latest Headlines

Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant

Rolapitant, Tesaro's experimental therapy for preventing some nasty side effects of chemo, has hit all the primary and secondary goals, helping boost the company's stock today and leaving it on track to deliver an NDA to the FDA in the next few months.

Tesaro's shares are routed on late-stage cancer drug data

Tesaro touted positive results for the primary endpoints laid out for the late-stage program it had underway for its top cancer drug prospect rolapitant, but investors soured on the drug after it failed to score secondary goals and drove the biotech's shares down by a hefty 22% this morning.

Tesaro insiders pledge support for $86M IPO gamble

Tesaro is betting that its management's rep and a late-stage program will help entice investors to snap up 6 million shares at $12 to $15 a share, worth an estimated $86.3 million.

Tesaro promises rapid progress with cancer drugs in $86M IPO

Tesaro has put together an SEC filing that makes one essential promise to prospective investors: This company is built for speed.